Products for Research Use Only

Fenofibrate-d6

CAT: 0804-HY-17356SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17356SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
CAS Number
1092484-56-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Cytochrome P450; Isotope-Labeled Compounds; PPAR
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cardiovascular Disease; Cancer
Purity
99.70
Solubility
10 mM in DMSO|DMSO : ≥ 15mg/mL
Smiles
ClC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(C(OC(C)C)=O)(C([2H])([2H])[2H])C([2H])([2H])[2H])=O
Molecular Formula
C20H15D6ClO4
Molecular Weight
366.87
Precautions
H302, H315, H319, H335
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Schelleman H, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78 (3) :639-48.|[3]Gong Y, et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Sep 30. pii: S2352-3964 (16) 30448-0.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
CYP2; CYP3